Skip to main content

Advertisement

Table 1 Patients’ characteristics and treatments before conception

From: Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients

  RA (n = 75) axSpA (n = 61)
Age at conception, years (median) 31 (21–40) 31 (22–41)
Age at diagnosis, years (median) 27 (20–38) 24 (17–33)
Rheumatoid factor-positive 50 (66)
HLA-B27-positive 43 (70.5)
axSpA with peripheral arthritis 27 (44.3)
Medication within 3 months before conception
 Methotrexatea 2 (2.7)
 NSAIDs 8 (10.7) 18 (29.5)
 TNFib 15 (20.0) 24 (39.3)
 Glucocorticosteroidsc 25 (33.3) 5 (8.2)
 DMARDs 29 (38.7) 5 (8.2)
  SSZ 18 (24.0) 5 (8.2)
  HCQ 8 (10.7)  
  SSZ and HCQ 3 (4.0)  
  1. Abbreviations: axSpA Axial spondyloarthritis, DMARD Disease-modifying antirheumatic drug, HCQ Hydrochloroquine, HLA Human leukocyte antigen, NSAID Nonsteroidal anti-inflammatory drug, RA Rheumatoid arthritis, SSZ Sulfasalazine, TNFi Tumor necrosis factor inhibitor
  2. aMethotrexate, discontinued 1 month before the planned conception
  3. bTNFi, discontinued at the time of the positive pregnancy test
  4. cPrednisone or prednisolone